RESEARCH MONOGRAPH · KDC-MN-326

Oleoylethanolamide (OEA)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

69/100

Endogenous satiety signal with interesting pharmacology and a still-unfinished therapeutic story

OEA is anandamide's monounsaturated cousin and pharmacologically pretty distinct. Where anandamide hits CB1, OEA is essentially CB1-inert and instead acts predominantly as a PPAR-alpha agonist with additional GPR119 activity and TRPV1 antagonism. The biology is mostly about lipid metabolism and satiety rather than central cannabinoid signaling.

The interesting work comes out of the Piomelli lab and dates back to the early 2000s. Rodriguez de Fonseca and colleagues showed OEA is released by enterocytes after a fat meal and acts as a vagal satiety signal, slowing gastric emptying and reducing food intake. It's basically a postprandial signal that says 'we've had enough fat.' Thats a real, replicated, mechanistically clean piece of biology.

The translational story has been harder. Several groups tried to develop OEA or OEA-mimetics as obesity therapeutics in the 2000s and 2010s and it never quite worked, partly because endogenous OEA has lousy oral PK (FAAH degrades it fast) and partly because the satiety effect from exogenous administration in humans turns out to be modest. PPAR-alpha is also a target with a complicated cardiometabolic profile (think fibrates) so there are off-effects to worry about.

What people miss: the gut-brain axis story with OEA is actually one of the cleaner examples of an endogenous lipid mediator with a defined sensory function, vagal afferent signaling, hypothalamic integration, behavioral output. For lipid-signaling research and enteric nervous system work it's a really useful tool.

Sourcing: synthetic OEA is available, less common than PEA but multiple suppliers, HPLC purity standard. Storage is similar to other fatty acid amides, light- and oxygen-sensitive, minus 80 long term.

What we like: clean PPAR-alpha agonism, well-mapped satiety pharmacology, useful tool for gut-brain axis research and metabolic signaling work.

What we dont like: the in vivo PK issues mean you usually need to either formulate it carefully or pair it with a FAAH inhibitor to get sustained tissue exposure. And the obesity-drug application has basically been a dead end despite the mechanism being plausible.

Solid research compound for the right questions. Underused outside metabolism circles.

Evidence: 65
Mechanism: 78
Reliability: 70
Safety: 85
Sourcing: 72
Value: 60
Signal: 55
Staying power: 68

Plain-language summary Intrigue 56 / 100

Oleoylethanolamide (OEA) is a fatty acid amide your small intestine releases after a fatty meal to tell your brain you are full. It activates PPAR-alpha and signals satiety through vagus nerve traffic and direct central nervous system effects, working through a pathway that is independent of leptin and ghrelin (the two satiety hormones most people know). The mechanism is biologically interesting because it ties dietary fat sensing directly to appetite shutdown. As a supplement it has been studied for weight loss with modest effects, and the broader research case sits more on biology than on robust clinical efficacy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous N-acylethanolamide (PPAR-alpha satiety signal)

An endogenous N-acylethanolamide; a PPAR-alpha agonist that signals satiety from the small intestine after fatty meals.

Abstract

Oleoylethanolamide (OEA; CAS 111-58-0; molecular formula C20H39NO2; molecular weight 325.53) is an endogenous N-acylethanolamide synthesized in the small intestine in response to dietary fat. The compound binds PPAR-alpha (Ki approximately 40 nM) with full agonist activity and signals satiety to the brain via vagal afferents and through direct CNS PPAR-alpha activation. The mechanism is distinct from leptin and ghrelin and represents a separate satiety pathway tied directly to fat intake. Pharmacological administration in rodents reduces food intake and body weight; clinical translation has been complicated by the short half-life (FAAH-mediated degradation). Used as the canonical PPAR-alpha satiety signal in metabolic and feeding research.

Mechanism of action

Endogenous PPAR-alpha agonist released postprandially from intestine; signals satiety via vagal afferents and central PPAR-alpha activation. Distinct from leptin and ghrelin pathways.

Reported research dose ranges

Research substrate; rodent studies 1 to 20 mg/kg.

References

Rodriguez de Fonseca F, et al. An anorexic lipid mediator regulated by feeding. Nature 2001.
Fu J, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003.
Piomelli D. A fatty gut feeling. Trends Endocrinol Metab 2013.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-326

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Oleoylethanolamide (OEA)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs